Sign up for Breaking News Email Alerts

Investor Center

Corporate Profile

Neuralstem's patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem’s NSI-566 spinal cord-derived stem cell therapy Phase II clinical trials for ALS concluded final surgeries in July 2014. Neuralstem has been awarded orphan status designation by the FDA         for its ALS cell therapy. In addition to ALS, the company is also in a Phase I NSI-566 trial in chronic spinal cord injury at University of California, San Diego School of Medicine, and is targeting other major central nervous system (CNS) conditions, such as ischemic stroke and acute spinal cord injury.

Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate neurons, possibly reversing pathologies associated with certain CNS conditions. The company has completed Phase Ia and Ib trials evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder (MDD), and is expecting to launch a Phase II NSI-189/MDD study in 2015. Additional indications might include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

Privacy and Terms ©Neuralstem, Inc. 2014

Information for Investors

ShareThis Copy and Paste